DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20150695

Iron status and choice of iron therapy during pregnancy: advantages and disadvantages

Ivana Chandra, Li-zhou Sun

Abstract


Iron deficiency anaemia (IDA) still becomes major health problem all over the world and pregnant women at particular risk. IDA is associated with negative outcomes for both mother and infant. Therefore, many laboratory assessments can be used as estimation of iron status during pregnancy, with haemoglobin (Hb) and serum ferritin (SF) as the most widely used tools. However, the uses of these two indicators remain controversies, because of physiological hemodilution that appears during pregnancy. Other methods are used to provide more accurate results of iron status, all with their advantages and drawback. Therapeutic options of IDA ranging from oral to intravenous therapy. Oral iron replacement became first choice for many years due to its safety and low cost. However, in some conditions such as severe anaemia and intolerance to oral iron, intravenous iron is preferable. Nowadays there are several preparations of intravenous iron in the market: Iron sucrose (IS), ferric gluconate, ferric carboxymaltose, iron dextran (high and low molecular weight dextran), iron isomaltoside and ferumoxytol. These preparations provide rapid replenishment of iron stores with good safety profiles. The present review summarizes methods to assess iron status during pregnancy, and choices of iron therapy, with their advantages and disadvantages. 


Keywords


Iron deficiency anaemia, Iron status, Pregnancy, Oral iron therapy, Intravenous iron therapy

Full Text:

PDF

References


Gangopadhyay R, Karoshi M, Keith L. Anaemia and pregnancy: A link to maternal chronic diseases. International Journal of Gynecology & Obstetrics. 2011;115:S11-S5.

Imdad A, Bhutta ZA. Routine iron/folate supplementation during pregnancy: effect on maternal anaemia and birth outcomes. Paediatric and perinatal epidemiology. 2012;26 Suppl 1:168-77.

Khalafallah AA, Dennis AE. Iron deficiency anaemia in pregnancy and postpartum: pathophysiology and effect of oral versus intravenous iron therapy. Journal of pregnancy. 2012;2012:630519.

Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW. Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. BMJ. 2013;346.

Arija V, Fargas F, March G, Abajo S, Basora J, Canals J, et al. Adapting iron dose supplementation in pregnancy for greater effectiveness on mother and child health: protocol of the ECLIPSES randomized clinical trial. BMC Pregnancy and Childbirth. 2014;14(33).

Barroso F, Allard S, Kahan BC, Connolly C, Smethurst H, Choo L, et al. Prevalence of maternal anaemia and its predictors: a multi-centre study. European journal of obstetrics, gynecology, and reproductive biology. 2011;159(1):99-105.

Haider BA, Yakoob MY, Bhutta ZA. Effect of multiple micronutrient supplementation during pregnancy on maternal and birth outcomes. BMC public health. 2011;11 Suppl 3:S19.

Vandevijvere S, Amsalkhir S, Van Oyen H, Egli I, Moreno-Reyes R. Iron status and its determinants in a nationally representative sample of pregnant women. Journal of the Academy of Nutrition and Dietetics. 2013;113(5):659-66.

Bresani C, Braga M, Felisberto D, Tavares-de-Melo C, Salvi D, Filho M. Accuracy of erythrogram and serum ferritin for the maternal anemia diagnosis (AMA): a phase 3 diagnostic study on prediction of the therapeutic responsiveness to oral iron in pregnancy. BMC Pregnancy and Childbirth. 2013;13(13).

Bencaiova G, Breymann C. Mild anemia and pregnancy outcome in a swiss collective. Journal of pregnancy. 2014;2014:307535.

Bencaiova G, Burkhardt T, Breymann C. Anemia--prevalence and risk factors in pregnancy. European journal of internal medicine. 2012;23(6):529-33.

Breymann C, Honegger C, Holzgreve W, Surbek D. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Archives of gynecology and obstetrics. 2010;282(5):577-80.

Breymann C. Iron Deficiency and Anaemia in Pregnancy: Modern Aspects of Diagnosis and Therapy. Blood Cells, Molecules, and Diseases. 2002;29(3):506-16.

Bashiri A, Burstein E, Sheiner E, Mazor M. Anemia during pregnancy and treatment with intravenous iron: review of the literature. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2003;110(1):2-7.

Short WW, Domagalski JE. Iron Deficiency Anemia: Evaluation and Management. Am Fam Physician. 2013;87(2):98-104.

Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Frontiers in Pharmacology. 2014;5.

Milman N. Prepartum anaemia: prevention and treatment. Annals of hematology. 2008;87(12):949-59.

Bánhidy F, Ács N, Puhó EH, Czeizel AE. Iron deficiency anemia: Pregnancy outcomes with or without iron supplementation. Nutrition. 2011;27(1):65-72.

Toblli JE, Angerosa M. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose. Drug design, development and therapy. 2014;8:2475-91.

Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochimica et biophysica acta. 2012;1823(9):1434-43.

Paesano R, Pietropaoli M, Gessani S, Valenti P. The influence of lactoferrin, orally administered, on systemic iron homeostasis in pregnant women suffering of iron deficiency and iron deficiency anaemia. Biochimie. 2009;91(1):44-51.

Koulaouzidis A, Said E, Cottier R, Saeed A. Soluble Transferrin Receptors and Iron Deficiency, a Step beyond Ferritin. A Systematic Review. Journal of gastrointestinal and liver diseases. 2009;18:345-52.

Casanueva E, Viteri FE, Mares-Galindo M, Meza-Camacho C, Loria A, Schnaas L, et al. Weekly iron as a safe alternative to daily supplementation for nonanemic pregnant women. Archives of medical research. 2006;37(5):674-82.

Balesaria S, Hanif R, Salama MF, Raja K, Bayele HK, McArdle H, et al. Fetal iron levels are regulated by maternal and fetal Hfe genotype and dietary iron. Haematologica. 2012;97(5):661-9.

Gambling L, Lang C, McArdle HJ. Fetal regulation of iron transport during pregnancy. Am J Clin Nutr. 2011;94(6 Suppl):1903S-7S.

Ribot B, Aranda N, Giralt M, Romeu M, Balaguer A, Arija V. Effect of different doses of iron supplementation during pregnancy on maternal and infant health. Annals of hematology. 2013;92(2):221-9.

Milman N, Agger AO, Nielsen OJ. Iron supplementation during pregnancy. Effect on iron status markers, serum erythropoietin and human placental lactogen. A placebo controlled study in 207 Danish women. Danish medical bulletin. 1991;38(6):471-6.

Aranda N, Ribot B, Viteri F, Cavalle P, Arija V. Predictors of haemoconcentration at delivery: association with low birth weight. European journal of nutrition. 2013;52(6):1631-9.

Momen A, Meshari A, Nuaim L, Saddique A, Abotalib Z, Khashogji T, et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology. 1996;69:121-4.

Aranda N, Ribot B, Garcia E, Viteri FE, Arija V. Pre-pregnancy iron reserves, iron supplementation during pregnancy, and birth weight. Early human development. 2011;87(12):791-7.

Madhavan Nair K, Bhaskaram P, Balakrishna N, Ravinder P, Sesikeran B. Response of hemoglobin, serum ferritin, and serum transferrin receptor during iron supplementation in pregnancy: A prospective study. Nutrition. 2004;20(10):896-9.

Braga F, Infusino I, Dolci A, Panteghini M. Soluble transferrin receptor in complicated anemia. Clinica chimica acta; international journal of clinical chemistry. 2014;431:143-7.

Haram K, Nilsen S, Ulvik R. Iron supplementation in pregnancy – evidence and controversies. Acta Obstetricia et Gynecologica Scandinavia. 2001;80:683-8.

Leonard AJ, Patterson AJ, Collins CE, Chalmers KA. Is soluble transferrin receptor a useful marker in early stage iron deficiency? e-SPEN Journal. 2013;8(5):e210-e2.

Labbe RF, Dewanji A. Iron assessment tests: transferrin receptor vis-a-vis zinc protoporphyrin. Clinical biochemistry. 2004;37(3):165-74.

Urrechaga E, Borque L, Escanero JF. Biomarkers of hypochromia: the contemporary assessment of iron status and erythropoiesis. BioMed research international. 2013;2013:603786.

Torino AB, Gilberti Mde F, da Costa E, de Lima GA, Grotto HZ. Evaluation of red cell and reticulocyte parameters as indicative of iron deficiency in patients with anemia of chronic disease. Revista brasileira de hematologia e hemoterapia. 2014;36(6):424-9.

Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clinica Chimica Acta. 2003;329(1-2):9-22.

Deazevedopaiva A, Rondo P, Guerrashinohara E, Silva C. The influence of iron, vitamin B, and folate levels on soluble transferrin receptor concentration in pregnant women. Clinica Chimica Acta. 2003;334(1-2):197-203.

Skikne BS. Serum transferrin receptor. American journal of hematology. 2008;83(11):872-5.

R'zik S, Loo M, Beguin Y. Reticulocyte transferrin receptor (TfR) expression and contribution to soluble TfR levels. Haematologica. 2001;86:244-51.

Young MF, Pressman E, Foehr ML, McNanley T, Cooper E, Guillet R, et al. Impact of maternal and neonatal iron status on placental transferrin receptor expression in pregnant adolescents. Placenta. 2010;31(11):1010-4.

Waters HM, Seal LH. A systematic approach to the assessment of erythropoiesis. Clinical & Laboratory Haematology. 2001;23(5):271-83.

Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clinical journal of the American Society of Nephrology: CJASN. 2006;1 Suppl 1:S4-8.

Lee EJ, Oh E-J, Park Y-J, Lee HK, Kim BK. Soluble Transferrin Receptor (sTfR), Ferritin, and sTfR/Log Ferritin Index in Anaemic Patients with Nonhematologic Malignancy and Chronic Inflammation. Clinical Chemistry. 2002;48(7):1118-21.

Thomason RW, Almiski MS. Evidence that stainable bone marrow iron following parenteral iron therapy does not correlate with serum iron studies and may not represent readily available storage iron. American journal of clinical pathology. 2009;131(4):580-5.

Zimmermann MB. Methods to assess iron and iodine status. The British journal of nutrition. 2008;99 Suppl 3:S2-9.

Lasthuizen E, Lindemans J, Langenhuijsen M. Erythrocyte zinc protoporphyrin testing in pregnancy. Acta Obstetricia et Gynecologica Scandinavia. 2000;79:660-6.

Miller JL. Iron Deficiency Anemia: A Common and Curable Disease. Cold Spring Harbor Perspectives in Medicine. 2013;3(7):a011866-a.

Habib F, Alabdin EH, Alenazy M, Nooh R. Compliance to iron supplementation during pregnancy. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2009;29(6):487-92.

Bencaiova G, von Mandach U, Zimmermann R. Iron prophylaxis in pregnancy: intravenous route versus oral route. European journal of obstetrics, gynecology, and reproductive biology. 2009;144(2):135-9.

WHO. Iron and folate supplementation. Geneva, World Health Organization. 2006.

Breymann C, Visca E, Huch R, Huch A. Efficacy and safety of intravenously administered iron sucrose with and without adjuvant recombinant human erythropoietin for the treatment of resistant iron-deficiency anemia during pregnancy. American journal of obstetrics and gynecology. 2001;184(4):662-7.

Santiago P. Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. The Scientific World Journal. 2012;2012:846824.

Ortiz R, Toblli JE, Romero JD, Monterrosa B, Frer C, Macagno E, et al. Efficacy and safety of oral iron(III) polymaltose complex versus ferrous sulfate in pregnant women with iron-deficiency anemia: a multicenter, randomized, controlled study. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2011;24(11):1347-52.

Froessler B, Collingwood J, Hodyl N, Dekker G. Intravenous ferric carboxymaltose for anaemia in pregnancy. BMC Pregnancy and Childbirth. 2014;14:115.

Casanueva E, F.E V. Iron and Oxidative Stress in Pregnancy. The Journal of nutrition. 2003;133:1700S-8S.

Scholl TO. Iron status during pregnancy: setting the stage for mother and infant. The American Journal of Clinical Nutrition. 2005;81(suppl):1218S-22S.

Cuciti C, Mayer D, Arnette R, Spielman F. Anaphylactoid reaction to intravenous sodium ferric gluconate complex during pregnancy.

International Journal of Obstetric Anesthesia. 2005;14:362-4.

Rampton D, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671-6.

Holm C, Thomsen L, Norgaard A, Roos J. Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum hemorrhage: study protocol for a randomized controlled trial. Trials. 2015;16:5.

Beguin Y, Jaspers A. Iron sucrose -- characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas. Expert Opin Pharmacother. 2014;15(14):2087-103.

Macdougall IC, Geisser P. Use of Intravenous Iron Supplementation in Chronic Kidney Disease: An Update. Iranian Journal of Kidney Diseases. 2013;7:9-22.

Lee ES, Park BR, Kim JS, Choi GY, Lee JJ, Lee IS. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Current medical research and opinion. 2013;29(2):141-7.

Froessler B, Cocchiaro C, Saadat-Gilani K, Hodyl N, Dekker G. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2013;26(7):654-9.

Abhilashini GD, Sagili H, Reddi R. Intravenous iron sucrose and oral iron for the treatment of iron deficiency anaemia in pregnancy. Journal of clinical and diagnostic research: JCDR. 2014;8(5):OC04-7.

Jahn MR, Andreasen HB, Futterer S, Nawroth T, Schunemann V, Kolb U, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2011;78(3):480-91.

Fishbane S. Safety in iron management. American Journal of Kidney Diseases. 2003;41:18-26.

Lyseng-Williamson K, Keating G. Ferric Carboxymaltose. Drugs. 2009;69(6):739-56.

Kuster M, Meli DN. Treatment of iron deficiency with intravenous ferric carboxymaltose in general practice: a retrospective database study. Journal of clinical medicine research. 2015;7(1):37-40.

Lu M, Cohen MH, Rieves D, Pazdur R. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American journal of hematology. 2010;85(5):315-9.

Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clinical journal of the American Society of Nephrology: CJASN. 2014;9(4):705-12.

McCormack P. Ferumoxytol. Drugs. 2012;72(15):2013-22.

Nordfjeld K, Andreasen H, Thomsen LL. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease. Drug design, development and therapy. 2012;6:43-51.